In the ruling, the ICDR rejected Napo's material breach claim, finding that Glenmark has complied with all of its obligations under the collaboration agreement. The ruling is an interim award addressing the issues presently before the ICDR. Certain other issues between the parties have been deferred to a second phase.

Glenmark Pharmaceuticals has an exclusive license from Napo Pharmaceuticals to distribute and commercialise Crofelemer in 140 emerging countries, including India, for indications related to HIV, use in acute adult and pediatric diarrhea. Crofelemer is a novel, first-in-class anti-diarrheal agent that has a physiological and different mechanism of action from traditional anti-diarrheal agents.